At the recent American Society of Hematology annual meeting, early data from the Mithic-FL1 Trial demonstrated impressive response rates with frontline mosunetuzumab (Lunsumio) in high-tumor-bulk ...
Changes are coming to the cold and cough aisle of your local pharmacy: U.S. officials are moving to phase out the leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback